Core Insights - Bristol Gate Capital Partners emphasizes investing in companies with strong free cash flows, disciplined capital allocation, and high dividend growth for superior risk-adjusted returns [1] - The market has shifted towards AI leaders since late 2022, leading to the fund's underperformance due to narrow breadth, although there is a recent shift supported by the outperformance of dividend-focused indices [1] - The firm's Data Science team's advancements in the Distant Future Model present strong opportunities for investors to buy into the strategy and mitigate risks in a concentrated market [1] Company Focus: Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. is highlighted as a leading contributor in the Q4 2025 investor letter, focusing on life sciences solutions, analytical instruments, specialty diagnostics, and biopharma services [2] - As of March 27, 2026, Thermo Fisher's share price was $473.36, with a one-month return of -6.93% and a 52-week loss of 4.87%, and a market capitalization of $175.846 billion [2] - The company experienced a rally in Q4, reaching a new 52-week high, driven by strong Q3 earnings that exceeded consensus expectations, and anticipates growth in 2026 as headwinds abate [3]

Core Viewpoint - Thermo Fisher Scientific Inc. (TMO) is a leading provider of life sciences solutions and is expected to announce its fiscal first-quarter earnings for 2026 soon, with analysts projecting a profit increase [1][2]. Financial Performance - Analysts anticipate TMO will report a diluted EPS of $5.31 for Q1 2026, reflecting a 3.1% increase from $5.15 in the same quarter last year [2]. - For the full fiscal year 2026, TMO's EPS is expected to reach $24.66, marking a 7.8% increase from $22.87 in fiscal 2025, with further growth projected to $27 in fiscal 2027, a 9.5% year-over-year rise [3]. Earnings History - TMO has consistently exceeded Wall Street's EPS estimates in its last four quarterly reports, with reported EPS figures surpassing estimates by margins ranging from 0.98% to 5.27% [4][5]. - The company's Q4 results showed an adjusted EPS of $6.57, exceeding expectations of $6.43, with revenue reported at $12.2 billion, above the forecast of $11.9 billion [5]. Analyst Ratings - The consensus among analysts is bullish, with a "Strong Buy" rating for TMO stock. Out of 23 analysts, 18 recommend a "Strong Buy," while two suggest a "Moderate Buy" and three a "Hold" [6]. - The average analyst price target for TMO is $665.28, indicating a potential upside of 36.1% from current levels [6]. Stock Performance - TMO stock has underperformed the S&P 500 Index, which gained 13.4% over the past 52 weeks, with TMO shares down 4.8% during the same period [4].

Core Insights - Emerald Wealth Partners reported a +3.1% (gross) and +3.0% (net) return for its Growth Equity Strategy in Q4 2025, contributing to a year-to-date return of 16.7% (gross) and +16.0% (net) [1] - Concerns about a potential bubble in AI markets and the impact of President Trump's trade policies were significant challenges in 2025 [1] Company Highlights - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as a leading contributor in the Q4 2025 investor letter, focusing on life sciences solutions and biopharma services [2][3] - As of March 16, 2026, Thermo Fisher's stock closed at $470.00, with a one-month return of -6.30% and a 52-week loss of 9.88% [2] - Thermo Fisher has a market capitalization of $174.598 billion [2] Investment Sentiment - Thermo Fisher was noted as a beneficiary of the onshoring trend in healthcare R&D and manufacturing to the U.S. [3] - The company ranked 34th on the list of the 40 Most Popular Stocks Among Hedge Funds, with 113 hedge fund portfolios holding its stock at the end of Q4, down from 121 in the previous quarter [3] - While Thermo Fisher is recognized for its potential, certain AI stocks are believed to offer greater upside potential with less downside risk [3]

Core Insights - Thermo Fisher Scientific Inc. (TMO) has a market capitalization of $202.8 billion and provides a range of life sciences solutions and services [1] - Over the past 52 weeks, TMO shares have declined by 2.4%, underperforming the S&P 500 Index, which gained 14.4% [1] - Year-to-date, TMO stock is down 6.8%, while the S&P 500 has risen by 1.4% [1] Performance Comparison - TMO has also underperformed the State Street Health Care Select Sector SPDR ETF (XLV), which increased by 6.2% over the past 52 weeks [2] - On January 29, TMO shares fell by 2.6% despite reporting better-than-expected Q4 results, with revenue of $12.2 billion and adjusted EPS of $6.57, both exceeding analyst estimates [4] - The company's revenue grew by 7.2% year-over-year, while adjusted EPS increased by 7.7% [4] Financial Outlook - Analysts project TMO's EPS to grow by 7.8% year-over-year to $24.65 for fiscal 2026 [5] - TMO has a strong earnings surprise history, exceeding consensus estimates in the last four quarters [5] - Among 23 analysts covering TMO, the consensus rating is a "Strong Buy," with 18 "Strong Buy," 2 "Moderate Buy," and 3 "Hold" ratings [5] Analyst Ratings and Price Targets - The configuration of analyst ratings has become more bullish, with 16 analysts suggesting a "Strong Buy" rating [7] - JPMorgan Chase & Co. maintained a "Buy" rating on TMO with a price target of $710, indicating a potential upside of 31.5% [7] - The mean price target is $662.95, representing a 22.8% premium, while the highest price target of $750 suggests a potential upside of 38.9% [7]

Core Insights - Baron Health Care Fund reported a 13.10% increase in the fourth quarter, outperforming the Russell 3000 Health Care Index's 11.92% and the Russell 3000 Index's 2.40% [1] - For the full year, the Fund returned 10.28%, while the benchmarks gained 14.56% and 17.15% respectively [1] - The Fund focuses on investing in businesses with sustainable competitive advantages and strong management, particularly in the healthcare sector, which is expected to show positive momentum through 2026 [1] Company Specifics - Thermo Fisher Scientific Inc. (NYSE:TMO) was highlighted as a key stock in the Fund's fourth-quarter letter, with a one-month return of -12.36% and a 52-week loss of 5.09% [2] - As of February 5, 2026, Thermo Fisher's stock closed at $542.36, with a market capitalization of $203.769 billion [2] - The Fund has increased its position in Thermo Fisher, citing improving end markets for life sciences tools and stable biopharmaceutical R&D investment [3] - Management of Thermo Fisher anticipates organic revenue growth of 3% to 6% for 2026 and 2027, with potential for mid-to-high single-digit adjusted operating income growth [3] - Long-term growth drivers in the life sciences tools industry are expected to enable Thermo Fisher to achieve over 7% organic revenue growth beyond 2027 [3]

Core Thesis - Thermo Fisher Scientific Inc. (TMO) is positioned as a strong investment opportunity in the healthcare and pharmaceutical sectors, benefiting from structural demand and a unique business model that minimizes risks associated with drug development [2][3]. Company Overview - Thermo Fisher provides a wide range of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services globally, making it a key player in the healthcare innovation landscape [2]. - The company commands approximately 15% of the global life sciences tools and services market, forming a duopoly with Danaher [3]. Market Dynamics - The healthcare demand is resilient due to aging populations, rising chronic diseases, and increased healthcare spending in emerging markets, which supports long-term growth for companies like Thermo Fisher [2]. - The shift towards more complex medicine, including biologics and precision therapies, increases the demand for infrastructure providers, positioning Thermo Fisher favorably within the ecosystem [3]. Business Model - Thermo Fisher's business model focuses on embedding itself throughout the drug development lifecycle, which reduces exposure to patent cliffs and demand volatility [4]. - The company generates significant revenue from high-margin consumables tied to its installed base, creating a recurring revenue stream that enhances financial stability [4]. Financial Performance - Recent operational results indicate improving fundamentals, with the company experiencing positive organic growth and an acceleration in demand from the pharmaceutical and biotech sectors [5]. - The disciplined approach to mergers and acquisitions (M&A) is a core value driver, enhancing capabilities and supporting robust free cash flow, which benefits shareholder returns [5].

Core Insights - Thermo Fisher Scientific Inc. (TMO) is a leading provider of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services, with a market cap of $218.2 billion [1] Financial Performance Expectations - Analysts expect TMO to report a profit of $6.44 per share for Q4 2025, reflecting a 5.6% increase from $6.10 per share in the same quarter last year [2] - For the full fiscal year 2025, TMO's EPS is projected to be $22.74, up 4% from $21.86 in fiscal 2024, and is expected to rise to $24.56 in fiscal 2026, an 8% year-over-year increase [3] Stock Performance - TMO stock has underperformed the S&P 500 Index, which gained 15.7% over the past 52 weeks, with TMO shares increasing by only 11.2% during the same period [4] - The stock also lagged behind the Health Care Select Sector SPDR Fund's 12.1% returns in the same timeframe [4] Market Challenges - The underperformance of TMO is attributed to weaknesses in China, pricing pressures, and cautious spending from academic and government sectors, with diagnostics in China still struggling [5] - While Europe shows modest improvement and the U.S. market remains stable but uncertain, these factors have impacted TMO's growth [5] Recent Earnings Report - On October 22, TMO shares rose by 1.7% following the release of Q3 results, where the adjusted EPS of $5.79 exceeded Wall Street's expectations of $5.50, and revenue reached $11.1 billion, surpassing the forecast of $10.9 billion [5] Analyst Ratings - The consensus opinion among analysts on TMO stock is bullish, with a "Strong Buy" rating from 18 out of 23 analysts, while two suggest a "Moderate Buy" and three give a "Hold" rating [6] - The average analyst price target for TMO is $636.90, indicating a potential upside of 8.9% from current levels [6]

Core Insights - The Artisan Value Fund's third-quarter 2025 performance was positive, with returns of 0.83% for Investor Class ARTLX, 0.91% for Advisor Class APDLX, and 0.90% for Institutional Class APHLX, compared to a 5.33% return for the Russell 1000 Value Index [1] Group 1: Market Context - The equity market rally continued in Q3 2025, driven by strong corporate earnings, increased AI investment, and expectations of economic support from US fiscal policy and lower interest rates [1] Group 2: Company Focus - Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. (NYSE:TMO) is highlighted as a key stock, providing life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services [2] - The stock experienced a one-month return of -0.75% but gained 11.93% over the last 52 weeks, closing at $580.74 per share on December 26, 2025, with a market capitalization of $218.19 billion [2] - Thermo Fisher was one of the top contributors to returns in Q3, alongside Lam Research and ASML, following purchases made during a market downturn [3]

Group 1: Market Overview - The S&P 500 Index experienced a significant surge in Q3 2025, driven by investor optimism due to expectations of monetary easing, strong consumer demand, and solid corporate earnings [1] - The Parnassus Core Equity Fund (Investor Shares) returned 2.57% in Q3 2025, underperforming the S&P 500 Index, which returned 8.12% [1] - Year-to-date, the fund's return was 9.89%, compared to 14.83% for the S&P 500 Index [1] Group 2: Company Focus - Thermo Fisher Scientific Inc. - Thermo Fisher Scientific Inc. (NYSE:TMO) is highlighted as a key stock in the Parnassus Core Equity Fund's Q3 2025 investor letter, offering a range of life sciences solutions and services [2][3] - The stock of Thermo Fisher Scientific Inc. had a one-month return of -3.69% but gained 8.83% over the last 52 weeks, closing at $575.70 per share with a market capitalization of $216.3 billion on December 22, 2025 [2] - The company recovered from being oversold earlier in the year, supported by favorable financial results and guidance that exceeded expectations [3] Group 3: Investment Sentiment - Thermo Fisher Scientific Inc. ranked 26th on the list of the 30 Most Popular Stocks Among Hedge Funds, with 121 hedge fund portfolios holding the stock at the end of Q3 2025, an increase from 117 in the previous quarter [3] - While acknowledging the potential of Thermo Fisher Scientific Inc. as an investment, the company believes that certain AI stocks may offer greater upside potential and carry less downside risk [3]

Core Viewpoint - Thermo Fisher Scientific Inc. (TMO) is recognized as one of the best stocks to buy in the S&P 500, with a consensus Strong Buy rating from analysts and a one-year price target indicating a potential upside of 12% [1]. Analyst Updates - Wells Fargo raised its price target for TMO to $675 from $635, citing improved clarity on U.S. pharmaceutical policies and positive growth projections [2]. - Citigroup upgraded TMO's rating to Buy from Neutral and increased its price target to $660 from $580, driven by favorable trends in onshoring and pharmaceutical spending [3]. Company Overview - Thermo Fisher Scientific is a leading provider of life sciences solutions, laboratory products, diagnostics, analytical instruments, and biopharma services, with an 8% gain year-to-date in 2025 [4].